科拓生物
(300858)
| 流通市值：34.28亿 | | | 总市值：46.61亿 |
| 流通股本：1.94亿 | | | 总股本：2.63亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 97,785,478.66 | 62,560,187.59 | 210,451,392.39 | 108,635,367.47 |
| 交易性金融资产 | 100,787,199.86 | 201,319,515.59 | 126,727,506.86 | 296,731,399.24 |
| 应收票据及应收账款 | 65,945,547.23 | 69,527,425.35 | 68,938,325.42 | 56,473,758.3 |
| 其中：应收票据 | 699,613.2 | 454,632 | 155,766 | - |
| 应收账款 | 65,245,934.03 | 69,072,793.35 | 68,782,559.42 | 56,473,758.3 |
| 预付款项 | 18,364,191.05 | 18,739,421.1 | 21,716,780.33 | 9,812,714.38 |
| 其他应收款合计 | 755,895.89 | 717,893.35 | 635,537.02 | 1,165,043.72 |
| 存货 | 48,283,886.58 | 44,074,348.55 | 42,808,856.93 | 46,599,458.64 |
| 一年内到期的非流动资产 | 616,302,970.34 | 611,792,841.34 | 585,996,744.32 | 425,496,669.38 |
| 其他流动资产 | 27,103,490.21 | 23,717,743.43 | 16,233,861.86 | 9,790,595.54 |
| 流动资产合计 | 975,328,659.82 | 1,032,449,376.3 | 1,073,509,005.13 | 954,705,006.67 |
| 非流动资产: | | | | |
| 长期股权投资 | 22,250,937.77 | 22,275,954.85 | 12,274,690.77 | 2,334,840.72 |
| 其他权益工具投资 | 1,231,554 | 1,231,554 | 1,231,554 | 1,231,554 |
| 固定资产 | 353,548,257.71 | 359,791,265.48 | 373,903,734.32 | 372,861,360.1 |
| 在建工程 | 341,594,975.74 | 298,862,799.55 | 234,009,714.18 | 172,069,465.9 |
| 使用权资产 | 3,357,093.22 | 3,137,825.62 | 3,169,064.43 | 3,767,245.24 |
| 无形资产 | 60,216,443.67 | 54,928,838.76 | 55,075,370.81 | 48,326,185.45 |
| 商誉 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 |
| 长期待摊费用 | 7,584,129.45 | 1,681,798.1 | 1,681,798.1 | 2,312,472.39 |
| 递延所得税资产 | 4,616,674.21 | 3,664,282.98 | 4,506,464.62 | 5,360,630.94 |
| 其他非流动资产 | 169,217,394.43 | 163,655,281.42 | 170,785,992.02 | 350,715,598.55 |
| 非流动资产合计 | 965,530,794.63 | 911,142,935.19 | 858,551,717.68 | 960,892,687.72 |
| 资产总计 | 1,940,859,454.45 | 1,943,592,311.49 | 1,932,060,722.81 | 1,915,597,694.39 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 50,061,581.78 | 48,939,745.89 | 56,960,199.4 | 47,727,805.31 |
| 应付账款 | 50,061,581.78 | 48,939,745.89 | 56,960,199.4 | 47,727,805.31 |
| 合同负债 | 18,397,271.14 | 19,701,332.02 | 15,485,311.36 | 23,126,832.19 |
| 应付职工薪酬 | 4,997,194.73 | 4,988,163.05 | 4,274,354.84 | 12,251,262.35 |
| 应交税费 | 7,641,035.5 | 5,629,987.23 | 12,704,261.93 | 7,181,533.09 |
| 其他应付款合计 | 907,260.13 | 42,441,916.33 | 2,858,268.96 | 3,024,240.07 |
| 应付股利 | - | 39,524,267.7 | - | - |
| 一年内到期的非流动负债 | 700,988.78 | 605,390.96 | 599,282.3 | 559,930.57 |
| 其他流动负债 | 1,541,539.04 | 1,841,318.65 | 1,232,791.81 | 2,316,912.77 |
| 流动负债合计 | 84,246,871.1 | 124,147,854.13 | 94,114,470.6 | 96,188,516.35 |
| 非流动负债: | | | | |
| 租赁负债 | 2,681,060.32 | 2,671,412.53 | 2,929,171.5 | 3,225,216.41 |
| 递延收益 | 26,194,783.73 | 24,105,633.19 | 23,083,905.18 | 25,142,849.04 |
| 递延所得税负债 | 1,461,265.95 | 1,418,810.52 | 1,292,259.87 | 1,473,316.7 |
| 非流动负债合计 | 30,337,110 | 28,195,856.24 | 27,305,336.55 | 29,841,382.15 |
| 负债合计 | 114,583,981.1 | 152,343,710.37 | 121,419,807.15 | 126,029,898.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 263,495,118 | 263,495,118 | 263,495,118 | 263,495,118 |
| 资本公积 | 1,107,041,979.46 | 1,107,041,979.46 | 1,107,785,475.46 | 1,107,041,979.46 |
| 其他综合收益 | -21.25 | 41.21 | 30.47 | 31.32 |
| 盈余公积 | 57,702,020.68 | 57,702,020.68 | 57,702,020.68 | 57,702,020.68 |
| 未分配利润 | 398,036,376.46 | 363,009,441.77 | 381,658,271.05 | 361,328,646.43 |
| 归属于母公司股东权益合计 | 1,826,275,473.35 | 1,791,248,601.12 | 1,810,640,915.66 | 1,789,567,795.89 |
| 股东权益合计 | 1,826,275,473.35 | 1,791,248,601.12 | 1,810,640,915.66 | 1,789,567,795.89 |
| 负债和股东权益合计 | 1,940,859,454.45 | 1,943,592,311.49 | 1,932,060,722.81 | 1,915,597,694.39 |
| 公告日期 | 2025-10-22 | 2025-08-20 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |